Close Menu

NEW YORK ─ The US Food and Drug Administration on Thursday granted Emergency Use Authorization to life science reagent company Zymo Research for its Quick SARS-CoV-2 rRT-PCR Kit for the detection of SARS-CoV-2 coronavirus.

The molecular kit, developed by the Irvine, California-based firm, has been authorized as a laboratory test for the detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens from patients suspected of COVID-19, the agency said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.